ANI Pharmaceuticals (ANIP) Expected to Announce Earnings on Friday

Key Points

• ANI is scheduled to report Q1 2026 results before the market opens on May 8 at 8:00 AM ET, with analysts expecting $1.28 EPS and $207.63M in revenue.
• Wall Street sentiment is positive with an average rating of "Moderate Buy" and an average price target of $107.33, including recent upgrades such as Guggenheim raising its target to $124.
• The stock opened at $79.45 (up 1.9%) with a 52-week range of $56.71–$99.50 and a market cap of $1.78B; insiders have sold 27,860 shares (~$2.11M) in the last three months while institutional investors own 76.05% of the company.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect ANI Pharmaceuticals to post earnings of $1.28 per share and revenue of $207.6280 million for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 8, 2026 at 8:00 AM ET.

ANI Pharmaceuticals Stock Up 1.9%

Shares of NASDAQ:ANIP opened at $79.45 on Friday. ANI Pharmaceuticals has a 52-week low of $56.71 and a 52-week high of $99.50. The firm has a market capitalization of $1.78 billion, a P/E ratio of 23.65 and a beta of 0.44. The stock has a 50 day moving average price of $76.36 and a 200-day moving average price of $81.29. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Guggenheim increased their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 14th. Finally, Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $107.33.

Insider Buying and Selling

In related news, insider Christopher Mutz sold 3,162 shares of the company's stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $71.64, for a total value of $226,525.68. Following the sale, the insider owned 91,309 shares in the company, valued at $6,541,376.76. This represents a 3.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Stephen P. Carey sold 7,312 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total value of $552,056.00. Following the completion of the sale, the chief financial officer owned 185,543 shares in the company, valued at $14,008,496.50. The trade was a 3.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,860 shares of company stock worth $2,111,581 over the last three months. Corporate insiders own 8.10% of the company's stock.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock valued at $736,000 after acquiring an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after acquiring an additional 423 shares in the last quarter. Jane Street Group LLC bought a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $2,706,000. Finally, Norges Bank bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $625,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.